Published in Oncology Business Week, May 31st, 2009
510k clearance to market the device makes it possible for cancer treatment centers in the United States to begin ordering, installing and using .decimal's propriety software, p.d, for bolus ECT. "We are now actively marketing bolus electron conformal therapy, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.